Company intelligence / Profile preview
Idience
Seocho-gu, Seoul, South Koreaidience.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
IDX-1197, a PARP inhibitor, is currently under Phase 1a and Phase 1b/2a clinical studies targeting multiple solid tumors. It has demonstrated superior outcome potential compared to currently available PARP inhibitors in non-clinical studies[4].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (PARP inhibitor)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Dong-A ST (strategic investment and joint research development agreement as of May 20, 2024)[6]
Beyond the preview
Go deeper on Idience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Idience.